You are here
Dr Lynn E. DeLisi - Founding Editor-in-Chief of Schizophrenia Research
Lynn E. DeLisi, MD is currently an inpatient Attending Psychiatrist in Brockton, VA, as well Professor of Psychiatry at Harvard Medical School. In addition, she is secretary of The Schizophrenia International Research Society (SIRS), and co-chair of the World Congress of Psychiatric Genetics, 2013.
She spent several years as a full-time staff research psychiatrist in the NIMH intramural research program, St. Elizabeths Hospital and Bethesda, Maryland. She then moved to The State University of New York at Stony Brook where she set up several research programs on the longitudinal biological outcome of schizophrenia, emphasizing both brain imaging and genetic studies. From 2001 through 2008 she was professor at New York University School of Medicine and Associate Director of the brain imaging division at The Nathan Kline Institute for Psychiatric Research. She moved to her current position in the Boston area in January 2009. She is a fellow of the American College of Neuropsychopharmacology, and has edited and authored over 300 books and manuscripts. Her book, 100 Questions and Answers about Schizophrenia: Painful Minds has been circulated widely among families of people with schizophrenia and medical students internationally and has been translated into several languages internationally.
Aside from currently editing the journal she co-founded with Dr Nasrallah, Schizophrenia Research, 25 years ago, she splits her time between caring for acute severely ill patients, teaching residents and medical students, as well as conducting research on the genetics of schizophrenia, as well as other projects relevant to substance abuse and PTSD. Her most recent focus has been on providing specific evaluations and treatments for recently returning veterans with serious mental illness. Dr Lynn E. DeLisi receives an unrestricted educational grant from Amgen that is administrated by the VA in Boston to study the genetics of schizophrenia; she receives no salary or personal funds from Amgen. Other than that she has no conflicts of interest to declare.